OBJECTIVE: To quantify the impact of tuberculosis (TB) co-infection on death and loss to follow-up (LTFU) 12 months after entry into an ART program. DESIGN: Prospective intervention study. METHODS: From May 2007 to 2008, patients undergoing pre-ART training in Durban, South Africa, were screened for pulmonary TB using mycobacterial culture. Subjects missing appointments for >3 months were phoned. Patients who could not be reached were considered LTFU. Deaths were ascertained by report from family members. We used the Kaplan-Meier method to estimate time to LTFU or death for 3 groups at enrollment as follows: (1) newly diagnosed with TB by sputum culture; (2) on TB treatment (ie, previously diagnosed); and (3) TB free. We evaluated the role of TB on mortality and LTFU using Cox proportional hazards models. RESULTS: Nine hundred fifty-one HIV-infected subjects were enrolled; 59% were female, and median baseline CD4 count was 90 cells per microliter (IQR: 41-148 cells/μL). One hundred forty-four (15%) were newly diagnosed with TB by sputum culture; an additional 199 (21%) were already on TB treatment. By 12 months, 26% newly diagnosed with TB at enrollment died or were LTFU, compared with 19% already on TB treatment, and 14% who were TB free (P = 0.001). Controlling for age, sex, smoking, CD4, and opportunistic infection history, subjects newly diagnosed with pulmonary TB were 76% more likely to die or be LTFU (hazard ratio: 1.76, 95% confidence interval: 1.20 to 2.60) than those without TB. CONCLUSIONS: HIV/TB co-infected individuals are more likely to die or be LTFU within 12 months of ART clinic entry in South Africa. These patients require intensive follow-up during ART initiation.
OBJECTIVE: To quantify the impact of tuberculosis (TB) co-infection on death and loss to follow-up (LTFU) 12 months after entry into an ART program. DESIGN: Prospective intervention study. METHODS: From May 2007 to 2008, patients undergoing pre-ART training in Durban, South Africa, were screened for pulmonary TB using mycobacterial culture. Subjects missing appointments for >3 months were phoned. Patients who could not be reached were considered LTFU. Deaths were ascertained by report from family members. We used the Kaplan-Meier method to estimate time to LTFU or death for 3 groups at enrollment as follows: (1) newly diagnosed with TB by sputum culture; (2) on TB treatment (ie, previously diagnosed); and (3) TB free. We evaluated the role of TB on mortality and LTFU using Cox proportional hazards models. RESULTS: Nine hundred fifty-one HIV-infected subjects were enrolled; 59% were female, and median baseline CD4 count was 90 cells per microliter (IQR: 41-148 cells/μL). One hundred forty-four (15%) were newly diagnosed with TB by sputum culture; an additional 199 (21%) were already on TB treatment. By 12 months, 26% newly diagnosed with TB at enrollment died or were LTFU, compared with 19% already on TB treatment, and 14% who were TB free (P = 0.001). Controlling for age, sex, smoking, CD4, and opportunistic infection history, subjects newly diagnosed with pulmonary TB were 76% more likely to die or be LTFU (hazard ratio: 1.76, 95% confidence interval: 1.20 to 2.60) than those without TB. CONCLUSIONS:HIV/TB co-infected individuals are more likely to die or be LTFU within 12 months of ART clinic entry in South Africa. These patients require intensive follow-up during ART initiation.
Authors: Bisola O Ojikutu; Hui Zheng; Rochelle P Walensky; Zhigang Lu; Elena Losina; Janet Giddy; Kenneth A Freedberg Journal: S Afr Med J Date: 2008-03
Authors: Rafaëlla Fa L'homme; Hanneke M J Nijland; Luuk Gras; Rob E Aarnoutse; Reinout van Crevel; Martin Boeree; Kees Brinkman; Jan M Prins; Job R Juttmann; David M Burger Journal: AIDS Date: 2009-04-27 Impact factor: 4.177
Authors: Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: Martin W G Brinkhof; Ben D Spycher; Constantin Yiannoutsos; Ralf Weigel; Robin Wood; Eugène Messou; Andrew Boulle; Matthias Egger; Jonathan A C Sterne Journal: PLoS One Date: 2010-11-30 Impact factor: 3.240
Authors: Daniel Westreich; Patrick MacPhail; Annelies Van Rie; Babatyi Malope-Kgokong; Prudence Ive; Dennis Rubel; Ronan Boulmé; Joseph Eron; Ian Sanne Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: David Moore; Cheryl Liechty; Paul Ekwaru; Willy Were; Gerald Mwima; Peter Solberg; George Rutherford; Jonathan Mermin Journal: AIDS Date: 2007-03-30 Impact factor: 4.177
Authors: Kate Clouse; Audrey E Pettifor; Mhairi Maskew; Jean Bassett; Annelies Van Rie; Frieda Behets; Cynthia Gay; Ian Sanne; Matthew P Fox Journal: J Acquir Immune Defic Syndr Date: 2013-02-01 Impact factor: 3.731
Authors: M Loveday; K Wallengren; J Brust; J Roberts; A Voce; B Margot; J Ngozo; I Master; G Cassell; N Padayatchi Journal: Int J Tuberc Lung Dis Date: 2015-02 Impact factor: 2.373
Authors: Stephen D Lawn; Anthony D Harries; Graeme Meintjes; Haileyesus Getahun; Diane V Havlir; Robin Wood Journal: AIDS Date: 2012-11-13 Impact factor: 4.177
Authors: Ramadhani S Mwiru; Donna Spiegelman; Christopher Duggan; George R Seage; Helen Semu; Guerino Chalamilla; Rodrick Kisenge; Wafaie W Fawzi Journal: J Int Assoc Provid AIDS Care Date: 2013-10-08
Authors: Morna Cornell; Michael Schomaker; Daniela Belen Garone; Janet Giddy; Christopher J Hoffmann; Richard Lessells; Mhairi Maskew; Hans Prozesky; Robin Wood; Leigh F Johnson; Matthias Egger; Andrew Boulle; Landon Myer Journal: PLoS Med Date: 2012-09-04 Impact factor: 11.069
Authors: Dam Anh Tran; Anh Duc Ngo; Anthony Shakeshaft; David P Wilson; Christopher Doran; Lei Zhang Journal: PLoS One Date: 2013-09-16 Impact factor: 3.240